<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Surgical management of hyperthyroidism</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Surgical management of hyperthyroidism</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Surgical management of hyperthyroidism</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Douglas S Ross, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sonia L Sugg, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David S Cooper, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jean E Mulder, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Sep 19, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The treatment of hyperthyroidism consists of both symptomatic relief and decreasing the production of thyroid hormone. The use of surgery as definitive therapy for hyperthyroidism varies with the cause of the disease and the characteristics of the patient.</p><p>Indications for surgical management of hyperthyroidism and preoperative preparation are reviewed here. Thyroidectomy is reviewed in detail elsewhere (see  <a class="medical medical_review" href="/z/d/html/2157.html" rel="external">"Thyroidectomy"</a>). Other treatment options are also discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/7879.html" rel="external">"Radioiodine in the treatment of hyperthyroidism"</a> and  <a class="medical medical_review" href="/z/d/html/7873.html" rel="external">"Treatment of toxic adenoma and toxic multinodular goiter"</a> and  <a class="medical medical_review" href="/z/d/html/7872.html" rel="external">"Graves' hyperthyroidism in nonpregnant adults: Overview of treatment", section on 'Selection of therapy'</a>.)</p><p class="headingAnchor" id="H18841177"><span class="h1">ROLE OF SURGERY</span><span class="headingEndMark"> — </span>The approach outlined below is consistent with Hyperthyroidism Management Guidelines from the American Thyroid Association (ATA) [<a href="#rid1">1</a>] and the American Association of Endocrine Surgeons [<a href="#rid2">2</a>].</p><p class="headingAnchor" id="H2"><span class="h2">Graves' disease</span><span class="headingEndMark"> — </span>Patients with Graves' disease can be treated with antithyroid drugs, radioiodine, or surgery. In the only randomized, prospective trial comparing these three therapies, each was equally effective in normalizing serum thyroid hormone concentrations within six weeks; after treatment, 95 percent or more of the patients were satisfied with their therapy [<a href="#rid3">3</a>]. Therefore, the choice of therapy should involve active discussion between clinician and patient  (<a class="graphic graphic_table graphicRef67833" href="/z/d/graphic/67833.html" rel="external">table 1</a>) [<a href="#rid4">4</a>]. The therapeutic approach to Graves' hyperthyroidism is reviewed in more detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/7872.html" rel="external">"Graves' hyperthyroidism in nonpregnant adults: Overview of treatment", section on 'Selection of therapy'</a>.)</p><p>A patient may prefer surgery over other modalities because of a desire to avoid radioiodine, avoid the potential side effects of antithyroid drugs, and to obtain rapid correction of hyperthyroidism. In addition, the following patients with Graves' hyperthyroidism may be better served by surgery:</p><p class="bulletIndent1"><span class="glyph">●</span>Patients with very large goiters (≥80 g) who may require multiple doses of radioiodine, which can result in asymmetric and limited shrinkage of the goiter.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with goiters causing upper airway obstruction or severe dysphagia.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients who also have a nonfunctional thyroid nodule with indeterminate, suspicious, or positive cytology on fine-needle aspiration, in whom surgery can both cure the hyperthyroidism and provide a definitive diagnosis of the nodule.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with coexisting hyperparathyroidism who are surgical candidates for parathyroidectomy, in whom surgery can cure the hyperthyroidism and hyperparathyroidism.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with moderate to severe thyroid eye disease in whom surgery is preferred over radioiodine since radioiodine may exacerbate thyroid eye disease, presumably by transiently increasing thyrotropin receptor antibody (TRAb) levels. Coadministering corticosteroids with radioiodine may prevent exacerbation of thyroid eye disease when it is mild. (See  <a class="medical medical_review" href="/z/d/html/7827.html" rel="external">"Treatment of thyroid eye disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pregnant women who are allergic to antithyroid drugs and are tolerating hyperthyroidism poorly have no alternative to surgery.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hyperthyroid women who want to get pregnant within the year, who wish to avoid the teratogenicity associated with <a class="drug drug_general" data-topicid="9830" href="/z/d/drug information/9830.html" rel="external">propylthiouracil</a> (PTU), and the increased risk of fetal hyperthyroidism due to the transient increase in TRAb levels after radioiodine.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients who have persistent hyperthyroidism despite treatment with antithyroid medication and radioiodine.</p><p></p><p>Additionally, the increased all-cause mortality and cardiovascular-related events associated with Graves' disease are correlated with persistent TSH suppression independent of treatment option [<a href="#rid5">5</a>]. Surgery typically results in more rapid correction of hyperthyroidism and also more effectively lowers TRAb [<a href="#rid6">6</a>].</p><p class="headingAnchor" id="H3"><span class="h2">Toxic adenoma and toxic multinodular goiter</span><span class="headingEndMark"> — </span>Surgery is used more commonly for the treatment of patients with a toxic adenoma or toxic multinodular goiter (MNG) than it is for Graves' hyperthyroidism. It is indicated for patients with obstructive goiters or very large goiters, those who need rapid and definitive correction of hyperthyroidism, and for patients with coexisting malignancy or primary hyperparathyroidism. (See  <a class="medical medical_review" href="/z/d/html/7873.html" rel="external">"Treatment of toxic adenoma and toxic multinodular goiter", section on 'Therapeutic approach'</a>.)</p><p>Surgery could also be considered in children and adolescents and, as noted above, may be preferable in patients with coexistent nonfunctioning nodules, especially if the goiters are large. Surgery is increasingly preferred by patients who have nodules in order to avoid the need for future assessments and interventions. Nodular thyroid tissue that remains following radioiodine treatment may develop calcifications over time, which may be interpreted as suspicious by radiologists on subsequent imaging and lead to thyroidectomy a decade or more after radioiodine treatment [<a href="#rid7">7</a>]. Substernal extension of the goiter is another possible indication for surgery [<a href="#rid8">8</a>]. (See  <a class="medical medical_review" href="/z/d/html/7820.html" rel="external">"Treatment of benign obstructive or substernal goiter", section on 'Substernal goiter'</a> and  <a class="medical medical_review" href="/z/d/html/7873.html" rel="external">"Treatment of toxic adenoma and toxic multinodular goiter", section on 'Indications'</a>.)</p><p class="headingAnchor" id="H18841322"><span class="h1">CONTRAINDICATIONS</span><span class="headingEndMark"> — </span>The presence of substantial comorbidity, including cardiopulmonary disease or other debilitating disease, is a relative contraindication to surgery. Surgery during pregnancy is associated with an increased risk of spontaneous abortion or premature delivery. For pregnant women who require surgery because of an inability to tolerate thionamides, the risks of surgery are minimized by operating during the second trimester. (See  <a class="medical medical_review" href="/z/d/html/7884.html" rel="external">"Hyperthyroidism during pregnancy: Treatment", section on 'Thionamide intolerance'</a>.)</p><p class="headingAnchor" id="H6617679"><span class="h1">EXTENT OF RESECTION</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Graves' disease</strong> – Most experts agree that total or near-total thyroidectomy rather than subtotal thyroidectomy is considered the optimal procedure [<a href="#rid1">1,2</a>]. The extent of surgery for Graves' hyperthyroidism was an area of controversy that paralleled the arguments for low versus high doses of radioiodine therapy; more aggressive surgery (total thyroidectomy) had a higher likelihood of inducing hypothyroidism, while less aggressive surgery (subtotal thyroidectomy) had a higher likelihood of recurrent hyperthyroidism. Surgical complications are lower when performed by surgeons with expertise in thyroid surgery [<a href="#rid1">1,2,9,10</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Total thyroidectomy</strong> – Total thyroidectomy involves removal of all thyroid tissue. Total thyroidectomy has a nearly 0 percent risk of recurrence; however, these patients require lifelong thyroxine (T4) replacement therapy [<a href="#rid11">11</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Subtotal thyroidectomy</strong> – Subtotal thyroidectomy is defined as either bilateral subtotal (leaving posterior rim on each thyroid lobe) or as the Hartley-Dunhill procedure (unilateral total lobectomy with contralateral subtotal lobectomy). Up to 60 percent of patients can maintain adequate thyroid function without thyroid hormone supplementation when there is a four- to seven-gram remnant [<a href="#rid1">1</a>], an important feature for patients without good access to thyroid hormone. However, the remnant predisposes to persistent or recurrent hyperthyroidism, as illustrated by the findings of a retrospective review of 415 patients who had subtotal thyroidectomy for Graves' disease; persistent or recurrent disease occurred in 28.7 percent with a median time to recurrence of 36 months [<a href="#rid12">12</a>]. Hypothyroidism developed in over 50 percent of patients. </p><p></p><p class="bulletIndent1">In a randomized trial of subtotal versus total thyroidectomy for Graves' disease involving 191 patients followed over five years, recurrent hyperthyroidism occurred in 4.7 percent of patients after subtotal versus none after total thyroidectomy, while transient hypoparathyroidism was seen in 6.8 and 12.6 percent, respectively, and permanent hypoparathyroidism in 0 and 0.5 percent, respectively [<a href="#rid13">13</a>].</p><p></p><p class="bulletIndent1">In a randomized trial comparing near total and total thyroidectomy in 205 patients with Graves' disease, there was no difference in the rate of transient hypoparathyroidism, an increased rate of reoperations for bleeding (3 versus 0 percent), and a higher rate of inadvertently removed parathyroid glands (13 versus 3 percent) in the near total thyroidectomy group [<a href="#rid14">14</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Toxic multinodular goiter</strong> – For patients with toxic multinodular goiter (MNG), total thyroidectomy should be performed [<a href="#rid1">1</a>]. (See  <a class="medical medical_review" href="/z/d/html/7873.html" rel="external">"Treatment of toxic adenoma and toxic multinodular goiter", section on 'Extent of resection'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Toxic adenoma</strong> – For patients with toxic adenoma without evidence of nodules in the contralateral lobe, ipsilateral lobectomy (or isthmusectomy if the adenoma is in the thyroid isthmus) is adequate. For patients with toxic adenoma and a coexisting nonfunctioning nodule in the contralateral lobe, total thyroidectomy may be warranted. The decision should be based upon results of fine-needle aspiration biopsy of the nonfunctioning nodule(s). (See  <a class="medical medical_review" href="/z/d/html/7873.html" rel="external">"Treatment of toxic adenoma and toxic multinodular goiter", section on 'Surgery'</a>.)</p><p></p><p class="headingAnchor" id="H6"><span class="h1">PREOPERATIVE PREPARATION</span></p><p class="headingAnchor" id="H1595358367"><span class="h2">Management of hyperthyroidism</span><span class="headingEndMark"> — </span>Patients with hyperthyroidism who are to undergo thyroid surgery should be treated with an antithyroid drug until the free T4 and T3 are normal [<a href="#rid1">1</a>]. It is not necessary to wait for the TSH to become normal, as this typically takes several additional weeks. Beta blockers can be used to control hyperthyroid symptoms in addition to thionamides. In patients with thionamide intolerance, beta blockers can be used alone or in conjunction with iodine, glucocorticoids, and possibly <a class="drug drug_general" data-topicid="9258" href="/z/d/drug information/9258.html" rel="external">cholestyramine</a>. Glucocorticoids have been used in conjunction with beta blockers and, in Graves' disease, iodine drops or iopanoic acid (if available) to prepare thyrotoxic patients for emergency surgery [<a href="#rid15">15</a>]. (See <a class="local">'Beta blockers'</a> below and <a class="local">'Thionamide therapy'</a> below and <a class="local">'Iodine'</a> below and <a class="local">'Patients unable to take a thionamide drug'</a> below.)</p><p>Patients with hyperthyroidism are at risk for developing thyroid storm, a rare and potentially fatal condition that usually occurs during surgery or in the first 18 hours after the procedure [<a href="#rid16">16,17</a>]. Treating hyperthyroidism prior to thyroid surgery reduces this risk. Some retrospective studies suggest surgery in patients with uncontrolled hyperthyroidism may be performed safely [<a href="#rid18">18,19</a>]. However, one study demonstrated a higher requirement for intraoperative beta blockers and another used a more stringent definition for the diagnosis of thyroid storm, potentially underestimating its occurrence. </p><p>There are some patients in whom euthyroidism cannot be achieved, or is not expected to be achieved, with thionamide therapy due to poor compliance or other patient-related factors. In such patients, the risk of thyroid storm may well be higher if thyroidectomy is deferred [<a href="#rid19">19,20</a>]. Surgery in a thyrotoxic patient ideally should be done at a center with experienced anesthesiologists.</p><p class="headingAnchor" id="H10949243"><span class="h3">Beta blockers</span><span class="headingEndMark"> — </span>Beta blockers ameliorate many of the symptoms of hyperthyroidism. They are often started as soon as the diagnosis of hyperthyroidism is made, even before obtaining a 24-hour radioiodine uptake or scan or the results of a thyrotropin receptor antibody (TRAb) level. In the absence of contraindications, we usually give <a class="drug drug_general" data-topicid="8940" href="/z/d/drug information/8940.html" rel="external">atenolol</a> (25 to 50 mg/day), which has the advantages of single daily dosing and beta-1 selectivity, but all drugs of this class effectively reduce symptoms in patients with hyperthyroidism.</p><p>In addition, for patients who are allergic to or cannot tolerate thionamides, beta blockers administered preoperatively may be as safe as a thionamide for preoperative preparation of the hyperthyroid patient [<a href="#rid18">18,21-23</a>]. As an example, in a randomized trial of <a class="drug drug_general" data-topicid="9627" href="/z/d/drug information/9627.html" rel="external">methimazole</a> versus <a class="drug drug_general" data-topicid="9645" href="/z/d/drug information/9645.html" rel="external">metoprolol</a> in 30 patients with newly diagnosed and untreated hyperthyroidism undergoing thyroid surgery, there was no difference in anesthesiologic or cardiovascular complications during surgery or in postoperative complications postsurgery [<a href="#rid21">21</a>]. (See  <a class="medical medical_review" href="/z/d/html/7874.html" rel="external">"Beta blockers in the treatment of hyperthyroidism"</a> and <a class="local">'Patients unable to take a thionamide drug'</a> below.)</p><p>Beta blockers may be tapered and discontinued after thyroid function tests have returned to normal.</p><p class="headingAnchor" id="H7"><span class="h3">Thionamide therapy</span><span class="headingEndMark"> — </span>Once the diagnosis of hyperthyroidism associated with an elevated TRAb level or a normal or increased radioiodine uptake is established, thionamides should be initiated with the aim of controlling hyperthyroidism prior to surgery. Thionamides alone are sufficient to achieve euthyroidism in approximately three to eight weeks. Prior to initiating thionamides, we obtain baseline blood tests, including a complete blood count (white count with differential) and a liver profile (bilirubin and transaminases). We do not use thionamides in patients with a baseline absolute neutrophil count &lt;1000 mm<sup>3</sup> or elevated liver transaminases (more than fivefold the upper limit of normal), except in selected patients after careful assessment of alternatives and risks. (See  <a class="medical medical_review" href="/z/d/html/7876.html" rel="external">"Thionamides in the treatment of Graves' disease"</a>.)</p><p><a class="drug drug_general" data-topicid="9627" href="/z/d/drug information/9627.html" rel="external">Methimazole</a> is recommended over <a class="drug drug_general" data-topicid="9830" href="/z/d/drug information/9830.html" rel="external">propylthiouracil</a> (PTU), except during the first trimester of pregnancy, because of its longer duration of action (allowing for single daily dosing) and a lesser degree of toxicity. (See  <a class="medical medical_review" href="/z/d/html/7876.html" rel="external">"Thionamides in the treatment of Graves' disease", section on 'Choice of drug'</a>.)</p><p>The initial dose of <a class="drug drug_general" data-topicid="9627" href="/z/d/drug information/9627.html" rel="external">methimazole</a> is 5 to 40 mg once daily depending upon disease severity [<a href="#rid1">1</a>]. For patients with larger goiters and/or more severe hyperthyroidism, we typically administer 20 or 30 mg daily. Patients should have their thyroid function assessed at four- to six-week intervals. The dose can be adjusted if the hyperthyroidism (as assessed clinically and by measurements of serum thyroid-stimulating hormone [TSH], T4, and T3) is not ameliorated within four to six weeks. (See  <a class="medical medical_review" href="/z/d/html/7876.html" rel="external">"Thionamides in the treatment of Graves' disease", section on 'Dosing'</a>.)</p><p><a class="drug drug_general" data-topicid="9627" href="/z/d/drug information/9627.html" rel="external">Methimazole</a> can be discontinued on the day of surgery.</p><p class="headingAnchor" id="H8"><span class="h3">Patients unable to take a thionamide drug</span><span class="headingEndMark"> — </span>Patients with toxic nodular goiter or toxic adenoma who are intolerant or unable to take thionamides should be pretreated with beta blockers alone, whereas patients with Graves' hyperthyroidism who are allergic to or are intolerant of thionamides can be treated with the combination of beta blockers and iodine [<a href="#rid18">18,21-24</a>]. (See <a class="local">'Iodine'</a> below.)</p><p>In the absence of contraindications, if blood pressure allows, a beta-adrenergic antagonist drug should be given in sufficient dose to maintain a pulse rate below 80 beats/minute with exercise [<a href="#rid23">23</a>]. Longer-acting drugs of this type, such as <a class="drug drug_general" data-topicid="8940" href="/z/d/drug information/8940.html" rel="external">atenolol</a>, are preferable because an oral dose taken one hour before surgery will maintain adequate blockade until the patient is able to take oral medications postoperatively. Supplemental intravenous <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">propranolol</a> can be administered as needed. (See  <a class="medical medical_review" href="/z/d/html/7874.html" rel="external">"Beta blockers in the treatment of hyperthyroidism"</a>.)</p><p>Although some studies suggest that <a class="drug drug_general" data-topicid="9258" href="/z/d/drug information/9258.html" rel="external">cholestyramine</a> (4 g by mouth three times daily) may help lower thyroid hormone levels during the preoperative management of refractory hyperthyroidism (eg, for people who cannot tolerate or who are resistant to thionamides) [<a href="#rid25">25,26</a>], it is rarely needed in this setting. (See  <a class="medical medical_review" href="/z/d/html/7885.html" rel="external">"Thyroid storm", section on 'Other therapies'</a>.)</p><p class="headingAnchor" id="H10949250"><span class="h3">Iodine</span><span class="headingEndMark"> — </span>In patients with Graves' disease, we administer inorganic iodine (eg, saturated solution of potassium iodide [SSKI]) for up to 10 days before surgery to decrease thyroid hormone secretion and to decrease the vascularity of the thyroid gland and subsequent surgical blood loss [<a href="#rid1">1,27</a>]. Preoperative iodine should not be used in patients with toxic multinodular goiter (MNG) or toxic adenoma, whose thyroid glands tend to be less hypervascular than in patients with Graves' disease, since iodine may actually exacerbate hyperthyroidism, especially in those patients not concurrently treated with antithyroid drugs preoperatively. (See  <a class="medical medical_review" href="/z/d/html/7878.html" rel="external">"Iodine in the treatment of hyperthyroidism"</a>.)</p><p>In a study comparing 28 patients who received iodine preoperatively with 31 who did not, rates of transient hypoparathyroidism (7 versus 26 percent) and transient hoarseness (0 versus 16 percent) were lower in the iodine group, suggesting that iodine also improves the safety of the surgery [<a href="#rid28">28</a>]. However, in a meta-analysis that included 223 patients given preoperative radioiodine and 287 controls, the iodine-treated patients had reduced vascularity and reduced intraoperative blood loss, but no change in recurrent laryngeal nerve damage, hypoparathyroidism, or postoperative hematoma [<a href="#rid29">29</a>].</p><p>Iodine can be given as SSKI (50 mg iodide per drop [0.05 mL], 1 to 2 drops three times daily [approximately 300 mg daily]) or <a class="drug drug_general" data-topicid="9455" href="/z/d/drug information/9455.html" rel="external">potassium iodide-iodine solution</a> (Lugol's) 8 mg iodide/iodine per drop, 5 to 7 drops three times daily. These solutions can be irritating and should be diluted in 240 mL or more of beverage and taken with food (see  <a class="medical medical_review" href="/z/d/html/7878.html" rel="external">"Iodine in the treatment of hyperthyroidism"</a>). Alternatively, the patient with Graves' disease can be given sodium ipodate or iopanoic acid (iodinated radiographic contrast agents) that not only contain iodine but also inhibit the extrathyroidal conversion of T4 to T3 and therefore rapidly lower serum T3 concentrations [<a href="#rid15">15</a>]. Neither is available in the United States. (See  <a class="medical medical_review" href="/z/d/html/7877.html" rel="external">"Iodinated radiocontrast agents in the treatment of hyperthyroidism"</a>.)</p><p class="headingAnchor" id="H492850330"><span class="h2">Measures to prevent postoperative hypocalcemia</span><span class="headingEndMark"> — </span>Calcium and 25-hydroxyvitamin D should be measured preoperatively and repleted if low or given prophylactically [<a href="#rid1">1</a>]. (See  <a class="medical medical_review" href="/z/d/html/2022.html" rel="external">"Vitamin D deficiency in adults: Definition, clinical manifestations, and treatment"</a> and <a class="local">'Hypocalcemia'</a> below.)</p><p>Transient biochemical hypocalcemia is common after thyroidectomy for Graves' disease [<a href="#rid30">30,31</a>]. Rates of symptomatic and biochemical postoperative hypocalcemia were reduced in one study when 1 g <a class="drug drug_general" data-topicid="9185" href="/z/d/drug information/9185.html" rel="external">calcium carbonate</a> was given three times daily for two weeks preoperatively [<a href="#rid32">32</a>]. Hypocalcemia was also less common when vitamin D levels were &gt;20 ng/mL prior to surgery [<a href="#rid33">33</a>]. In patients at high risk for hypoparathyroidism, <a class="drug drug_general" data-topicid="9183" href="/z/d/drug information/9183.html" rel="external">calcitriol</a> can be started pre- or perioperatively [<a href="#rid34">34-36</a>]. Since the onset of action for calcitriol may be several days, starting calcitriol three days prior to scheduled surgery in patients at high risk for postoperative hypoparathyroidism may prevent a delay in hospital discharge. (See <a class="local">'Hypocalcemia'</a> below.)</p><p class="headingAnchor" id="H18841213"><span class="h1">COMPLICATIONS</span><span class="headingEndMark"> — </span>Complications of thyroid surgery include wound infection, keloid formation at the site of the incision, transient and permanent hypoparathyroidism, and recurrent or superior laryngeal nerve palsy. (See  <a class="medical medical_review" href="/z/d/html/2157.html" rel="external">"Thyroidectomy", section on 'Complications'</a>.)</p><p>Permanent problems should occur in less than 1 to 2 percent of patients, although slightly higher complication rates have been described. As an example, in a series of 380 patients with hyperthyroidism who underwent surgery (98 percent subtotal thyroidectomy), complications included [<a href="#rid37">37</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Transient vocal cord paralysis in 3 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Prolonged postoperative hypocalcemia in 3 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Permanent hypoparathyroidism in 1 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Recurrent hyperthyroidism in 2 percent</p><p></p><p>In the Nationwide Inpatient Sample database, complications of total thyroidectomy were higher in surgeries done for Graves' disease than for thyroid cancer and multinodular goiter [<a href="#rid38">38</a>].</p><p class="headingAnchor" id="H9"><span class="h1">POSTOPERATIVE MANAGEMENT</span><span class="headingEndMark"> — </span>Beta blockers, if administered, should be tapered and discontinued after thyroidectomy. Antithyroid drugs can be discontinued at the time of thyroidectomy.</p><p class="headingAnchor" id="H10949435"><span class="h2">Hypocalcemia</span><span class="headingEndMark"> — </span>In the first 24 hours after total thyroidectomy for hyperthyroidism, transient biochemical hypocalcemia is common, occurring in 60 to 90 percent of patients [<a href="#rid11">11,30,31,39</a>]. Permanent hypoparathyroidism is uncommon, occurring in approximately 1 percent of patients [<a href="#rid11">11</a>].</p><p>Patients should be monitored for postoperative hypocalcemia and provided with education on the signs and symptoms of hypocalcemia. Some patients are routinely given calcium and <a class="drug drug_general" data-topicid="9183" href="/z/d/drug information/9183.html" rel="external">calcitriol</a> supplementation, whereas others are supplemented if the calcium level declines. When the risk of post-thyroidectomy hypocalcemia is high (eg, if the surgery was difficult and the surgeon feels the parathyroids may have been compromised or if the intraoperative or postoperative PTH levels are less than 10 to 15 pg/mL), routine supplementation with calcium and calcitriol is preferred.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Routine supplementation</strong> – Routine postoperative supplementation of calcium and <a class="drug drug_general" data-topicid="9183" href="/z/d/drug information/9183.html" rel="external">calcitriol</a> may decrease the development of hypocalcemia symptoms and allow for earlier discharge [<a href="#rid40">40</a>]. In many centers, a serum parathyroid hormone (PTH) level is checked in the immediate postoperative period and is used to predict risk of hypocalcemia [<a href="#rid41">41,42</a>]. In several studies, a postoperative (one to six hours) serum PTH level &lt;10 to 15 pg/mL was predictive of postoperative hypocalcemia [<a href="#rid43">43-45</a>].</p><p></p><p class="bulletIndent1">A typical prophylactic dose of oral <a class="drug drug_general" data-topicid="9185" href="/z/d/drug information/9185.html" rel="external">calcium carbonate</a> is approximately 2 to 3 g of elemental calcium given in two to four divided doses daily. This can be tapered over two to six weeks depending upon hypocalcemic symptoms and serum calcium determinations. <a class="drug drug_general" data-topicid="9183" href="/z/d/drug information/9183.html" rel="external">Calcitriol</a> is initially administered at a dose of 0.5 mcg daily for one to two weeks and increased or decreased thereafter depending upon the calcium and intact PTH levels [<a href="#rid1">1</a>]. Patients can be discharged if they are asymptomatic and have stable serum calcium levels (at least 7.8 mg/dL [1.95 mmol/L]).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Supplementation as needed</strong> – If calcium is not routinely administered after near-total or total thyroidectomy, serum calcium and albumin should be measured on the evening of surgery and the next morning. Oral calcium and <a class="drug drug_general" data-topicid="9183" href="/z/d/drug information/9183.html" rel="external">calcitriol</a> supplementation should be administered based upon the results of the serum calcium corrected for albumin  (<a class="graphic graphic_table graphicRef59019" href="/z/d/graphic/59019.html" rel="external">table 2</a>).</p><p></p><p>The management of post-thyroidectomy hypoparathyroidism is reviewed in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/7821.html" rel="external">"Differentiated thyroid cancer: Surgical treatment", section on 'Hypoparathyroidism'</a>.)</p><p class="headingAnchor" id="H10949470"><span class="h2">Hypothyroidism</span><span class="headingEndMark"> — </span>The frequency of postoperative hypothyroidism is dependent upon the size of the surgical remnant. For patients with Graves' disease or toxic multinodular goiter (MNG) who had near-total or total thyroidectomy, thyroid hormone replacement (T4) should be initiated prior to discharge in a euthyroid patient at a dose of approximately 1.6 mcg/kg body weight daily. If the patient was still hyperthyroid at the time of surgery, thyroid hormone replacement should be delayed until levels fall into the normal range; the interval can be estimated based on the week-long half-life of T4. Older patients and those with coronary disease or multiple coronary risk factors should initially be treated with approximately 20 percent less than the full calculated replacement dose to avoid the potential complications of overtreatment.</p><p>Serum TSH should be measured approximately six weeks after discharge and the dose increased by 12 to 25 mcg/day if the TSH remains above the normal reference range. Serum TSH should be remeasured approximately six weeks after each dose adjustment. (See  <a class="medical medical_review" href="/z/d/html/7855.html" rel="external">"Treatment of primary hypothyroidism in adults", section on 'Dose and monitoring'</a>.)</p><p>Patients with Graves' disease who have subtotal thyroidectomy and are not hypothyroid soon after surgery need to be monitored for possible hypothyroidism (or recurrent hyperthyroidism) for the rest of their lives.</p><p>Hypothyroidism is less common after lobectomy or isthmusectomy for toxic adenoma. Serum TSH and free T4 levels should be measured four to six weeks after surgery. Thyroid hormone should be initiated only if the TSH rises and remains above the normal reference range.</p><p class="headingAnchor" id="H1034696313"><span class="h2">Persistent hyperthyroidism</span><span class="headingEndMark"> — </span>If hyperthyroidism persists or recurs after near-total thyroidectomy for Graves' disease, patients should be treated with radioiodine because repeat surgery is associated with a high risk of complications. (See  <a class="medical medical_review" href="/z/d/html/7879.html" rel="external">"Radioiodine in the treatment of hyperthyroidism", section on 'Indications'</a>.)</p><p class="headingAnchor" id="H944123112"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/109107.html" rel="external">"Society guideline links: Hyperthyroidism"</a>.)</p><p class="headingAnchor" id="H10"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/15437.html" rel="external">"Patient education: Hyperthyroidism (overactive thyroid) (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/z/d/html/2178.html" rel="external">"Patient education: Hyperthyroidism (overactive thyroid) (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/z/d/html/2168.html" rel="external">"Patient education: Antithyroid drugs (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H18841476"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Role of surgery</strong> – The treatment of hyperthyroidism consists of both symptomatic relief and decreasing the production of thyroid hormone. The use of surgery as definitive therapy for hyperthyroidism varies with the cause of the disease and the characteristics of the patient. A patient may prefer surgery over other modalities to treat hyperthyroidism because of a desire to avoid radioiodine, avoid the potential side effects of antithyroid drugs, and obtain rapid correction of hyperthyroidism. Patients with symptoms or signs of compression/obstruction, a need for rapid return to euthyroidism, or coexisting thyroid cancer require surgery. (See <a class="local">'Role of surgery'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Contraindications to surgery</strong> – The presence of substantial comorbidity, including cardiopulmonary disease or other debilitating disease, is a relative contraindication to surgery. Surgery during pregnancy is associated with an increased risk of spontaneous abortion or premature delivery. For pregnant women who require surgery because of an inability to tolerate thionamides, the risks of surgery are minimized by operating during the second trimester. (See <a class="local">'Contraindications'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Preoperative preparation</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Beta blockers</strong> – Assuming there are no contraindications to its use,<strong> </strong>we recommend<strong> </strong>using a beta blocker for patients with moderate to severe hyperadrenergic symptoms until euthyroidism is achieved by thionamides or surgery (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>). We typically start with <a class="drug drug_general" data-topicid="8940" href="/z/d/drug information/8940.html" rel="external">atenolol</a> 25 to 50 mg daily and increase the dose as needed (up to 200 mg daily) to reduce pulse to less than 90 beats per minute if blood pressure allows. (See  <a class="medical medical_review" href="/z/d/html/7874.html" rel="external">"Beta blockers in the treatment of hyperthyroidism"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Thionamides</strong> – Patients with hyperthyroidism are at risk for developing thyroid storm, a rare condition that usually occurs during surgery or in the first 18 hours after the procedure.</p><p></p><p class="bulletIndent2">For patients with hyperthyroidism associated with an elevated thyrotropin receptor antibody (TRAb) level or a normal or elevated radioiodine uptake who are to undergo thyroidectomy, we suggest treating with a thionamide (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). <a class="drug drug_general" data-topicid="9627" href="/z/d/drug information/9627.html" rel="external">Methimazole</a> is preferred over <a class="drug drug_general" data-topicid="9830" href="/z/d/drug information/9830.html" rel="external">propylthiouracil</a> (PTU), except during the first trimester of pregnancy, because of its longer duration of action (allowing for single daily dosing) and a lesser degree of toxicity. The initial dose of methimazole is 5 to 40 mg once daily. For patients with larger goiters and/or more severe hyperthyroidism, we typically administer 20 or 30 mg daily. Thionamides alone are sufficient to achieve euthyroidism in approximately three to eight weeks. (See <a class="local">'Preoperative preparation'</a> above and  <a class="medical medical_review" href="/z/d/html/7876.html" rel="external">"Thionamides in the treatment of Graves' disease"</a> and  <a class="medical medical_review" href="/z/d/html/7876.html" rel="external">"Thionamides in the treatment of Graves' disease", section on 'Choice of drug'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Thionamide intolerance</strong> – Patients with toxic nodular goiter or toxic adenoma who are intolerant or unable to take thionamides should be pretreated with beta blockers alone, whereas patients with Graves' hyperthyroidism who are allergic to or are intolerant of thionamides can be treated with the combination of beta blockers and iodine. (See <a class="local">'Patients unable to take a thionamide drug'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Iodine if Graves' disease</strong> – For patients with Graves' hyperthyroidism, we suggest adding potassium iodine solution to decrease the vascularity of the thyroid gland and surgical blood loss (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). We typically use saturated solution of potassium iodide (SSKI, 50 mg iodide per drop [0.05 mL], 1 to 2 drops three times daily [approximately 300 mg daily]) for up to 10 days before surgery. (See <a class="local">'Preoperative preparation'</a> above and  <a class="medical medical_review" href="/z/d/html/7878.html" rel="external">"Iodine in the treatment of hyperthyroidism", section on 'Role of iodine'</a>.)</p><p></p><p class="bulletIndent2">Preoperative iodine should not be used in patients with toxic MNG or toxic adenoma, whose thyroid glands tend to be less hypervascular than in patients with Graves' disease, since iodine may actually exacerbate hyperthyroidism especially in those patients not concurrently treated with antithyroid drugs preoperatively.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Calcium and vitamin D supplementation for prevention</strong> – To prevent postoperative hypocalcemia, serum calcium and 25-hydroxyvitamin D should be assessed preoperatively and replaced, if necessary. (See <a class="local">'Measures to prevent postoperative hypocalcemia'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Postoperative management</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Hypocalcemia</strong> – Patients should be monitored for postoperative hypocalcemia and either routinely provided with calcium and <a class="drug drug_general" data-topicid="9183" href="/z/d/drug information/9183.html" rel="external">calcitriol</a> supplementation or supplemented if the calcium level declines. When the risk of post-thyroidectomy hypocalcemia is high (eg, if the surgery was difficult and the surgeon feels the parathyroids may have been compromised or if the intraoperative or postoperative PTH levels are less than 10 to 15 pg/mL), routine supplementation of calcium and calcitriol is preferred. (See <a class="local">'Hypocalcemia'</a> above.)</p><p></p><p class="bulletIndent2">A typical prophylactic dose of oral <a class="drug drug_general" data-topicid="9185" href="/z/d/drug information/9185.html" rel="external">calcium carbonate</a> is approximately 2 to 3 g of elemental calcium by mouth given in two to four divided doses daily. This can be tapered over two to six weeks depending upon hypocalcemic symptoms and serum calcium determinations. <a class="drug drug_general" data-topicid="9183" href="/z/d/drug information/9183.html" rel="external">Calcitriol</a> is administered at a dose of 0.5 mcg daily for one to two weeks and increased or decreased thereafter depending upon the calcium and intact PTH levels.</p><p></p><p class="bulletIndent2">If calcium is not routinely administered after near-total or total thyroidectomy, serum calcium and albumin should be measured on the evening of surgery and the next morning. Oral calcium and <a class="drug drug_general" data-topicid="9183" href="/z/d/drug information/9183.html" rel="external">calcitriol</a> supplementation should be administered based upon the results of the serum calcium corrected for albumin  (<a class="graphic graphic_table graphicRef59019" href="/z/d/graphic/59019.html" rel="external">table 2</a>). (See <a class="local">'Hypocalcemia'</a> above and  <a class="medical medical_review" href="/z/d/html/7821.html" rel="external">"Differentiated thyroid cancer: Surgical treatment", section on 'Hypoparathyroidism'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Thyroid hormone replacement</strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Graves' disease or toxic MNG</strong> – For patients with Graves' disease or toxic MNG who had near-total or total thyroidectomy, thyroid hormone replacement (T4) should be initiated prior to discharge in euthyroid patients at a dose of approximately 1.6 mcg/kg body weight daily. If the patient was still hyperthyroid at the time of surgery, thyroid hormone replacement should be delayed until levels fall into the normal range; the interval can be estimated based on the week-long half-life of T4. Older patients and those with coronary disease or multiple coronary risk factors should initially be treated with approximately 20 percent less than the calculated full replacement dose to avoid overtreatment. (See <a class="local">'Hypothyroidism'</a> above.)</p><p></p><p class="bulletIndent3">Serum thyroid-stimulating hormone (TSH) should be measured in approximately six weeks and the dose increased by 12 to 25 mcg/day if the TSH remains above the normal reference range. (See <a class="local">'Hypothyroidism'</a> above.)</p><p></p><p class="bulletIndent3">Patients with Graves' disease who have subtotal thyroidectomy and are not hypothyroid soon after surgery need to be monitored for possible hypothyroidism (or recurrent hyperthyroidism) for the rest of their lives.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Toxic adenoma</strong> – Hypothyroidism is less common after lobectomy or isthmusectomy for toxic adenoma. Serum TSH and free T4 levels should be measured four to six weeks after surgery. Thyroid hormone should be initiated only if the TSH rises and remains above the normal reference range. (See <a class="local">'Hypothyroidism'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Ross DS, Burch HB, Cooper DS, et al. 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis. Thyroid 2016; 26:1343.</a></li><li><a class="nounderline abstract_t">Patel KN, Yip L, Lubitz CC, et al. The American Association of Endocrine Surgeons Guidelines for the Definitive Surgical Management of Thyroid Disease in Adults. Ann Surg 2020; 271:e21.</a></li><li><a class="nounderline abstract_t">Törring O, Tallstedt L, Wallin G, et al. Graves' hyperthyroidism: treatment with antithyroid drugs, surgery, or radioiodine--a prospective, randomized study. Thyroid Study Group. J Clin Endocrinol Metab 1996; 81:2986.</a></li><li><a class="nounderline abstract_t">Ross DS. Radioiodine therapy for hyperthyroidism. N Engl J Med 2011; 364:542.</a></li><li><a class="nounderline abstract_t">Okosieme OE, Taylor PN, Evans C, et al. Primary therapy of Graves' disease and cardiovascular morbidity and mortality: a linked-record cohort study. Lancet Diabetes Endocrinol 2019; 7:278.</a></li><li><a class="nounderline abstract_t">Nalla P, Young S, Sanders J, et al. Thyrotrophin receptor antibody concentration and activity, several years after treatment for Graves' disease. Clin Endocrinol (Oxf) 2019; 90:369.</a></li><li><a class="nounderline abstract_t">Schenke SA, Wuestemann J, Zimny M, Kreissl MC. Ultrasound Assessment of Autonomous Thyroid Nodules before and after Radioiodine Therapy Using Thyroid Imaging Reporting and Data System (TIRADS). Diagnostics (Basel) 2020; 10.</a></li><li><a class="nounderline abstract_t">Katlic MR, Grillo HC, Wang CA. Substernal goiter. Analysis of 80 patients from Massachusetts General Hospital. Am J Surg 1985; 149:283.</a></li><li><a class="nounderline abstract_t">Hauch A, Al-Qurayshi Z, Randolph G, Kandil E. Total thyroidectomy is associated with increased risk of complications for low- and high-volume surgeons. Ann Surg Oncol 2014; 21:3844.</a></li><li><a class="nounderline abstract_t">Adam MA, Thomas S, Youngwirth L, et al. Is There a Minimum Number of Thyroidectomies a Surgeon Should Perform to Optimize Patient Outcomes? Ann Surg 2016.</a></li><li><a class="nounderline abstract_t">Palit TK, Miller CC 3rd, Miltenburg DM. The efficacy of thyroidectomy for Graves' disease: A meta-analysis. J Surg Res 2000; 90:161.</a></li><li><a class="nounderline abstract_t">Lin YS, Lin JD, Hsu CC, Yu MC. The long-term outcomes of thyroid function after subtotal thyroidectomy for Graves' hyperthyroidism. J Surg Res 2017; 220:112.</a></li><li><a class="nounderline abstract_t">Barczyński M, Konturek A, Hubalewska-Dydejczyk A, et al. Randomized clinical trial of bilateral subtotal thyroidectomy versus total thyroidectomy for Graves' disease with a 5-year follow-up. Br J Surg 2012; 99:515.</a></li><li><a class="nounderline abstract_t">Maurer E, Maschuw K, Reuss A, et al. Total Versus Near-total Thyroidectomy in Graves Disease: Results of the Randomized Controlled Multicenter TONIG-trial. Ann Surg 2019; 270:755.</a></li><li><a class="nounderline abstract_t">Baeza A, Aguayo J, Barria M, Pineda G. Rapid preoperative preparation in hyperthyroidism. Clin Endocrinol (Oxf) 1991; 35:439.</a></li><li><a class="nounderline abstract_t">Lee KS, Kim K, Hur KB, Kim CK. The role of propranolol in the preoperative preparation of patients with Graves' disease. Surg Gynecol Obstet 1986; 162:365.</a></li><li><a class="nounderline abstract_t">Lukomsky GI, Ivanova NA, Kabanova GM. Preoperative treatment of patients with thyrotoxicosis. Am J Surg 1984; 147:263.</a></li><li><a class="nounderline abstract_t">Short HL, Tamatea J, Conaglen HM, et al. The safety of anaesthetising biochemically hyperthyroid patients undergoing thyroidectomy-a retrospective cohort study. Anaesth Intensive Care 2018; 46:396.</a></li><li><a class="nounderline abstract_t">Fazendin J, Zmijewski P, Allahwasaya A, et al. Surgical Treatment of Hyperthyroidism Can Be Performed Safely Before a Euthyroid State is Achieved. Thyroid 2023; 33:691.</a></li><li><a class="nounderline abstract_t">Ross DS. Is the Risk of Thyroid Storm Higher When Patient-Related Factors Delay Treatment of Hyperthyroidism, Or Is It Higher When Patients Undergo Thyroidectomy While Still Thyrotoxic? Thyroid 2023; 33:664.</a></li><li><a class="nounderline abstract_t">Adlerberth A, Stenström G, Hasselgren PO. The selective beta 1-blocking agent metoprolol compared with antithyroid drug and thyroxine as preoperative treatment of patients with hyperthyroidism. Results from a prospective, randomized study. Ann Surg 1987; 205:182.</a></li><li><a class="nounderline abstract_t">Vickers P, Garg KM, Arya R, et al. The role of selective beta 1-blocker in the preoperative preparation of thyrotoxicosis: a comparative study with propranolol. Int Surg 1990; 75:179.</a></li><li><a class="nounderline abstract_t">Feek CM, Sawers JS, Irvine WJ, et al. Combination of potassium iodide and propranolol in preparation of patients with Graves' disease for thyroid surgery. N Engl J Med 1980; 302:883.</a></li><li><a class="nounderline abstract_t">Fischli S, Lucchini B, Müller W, et al. Rapid preoperative blockage of thyroid hormone production / secretion in patients with Graves' disease. Swiss Med Wkly 2016; 146:w14243.</a></li><li><a class="nounderline abstract_t">Yang Y, Hwang S, Kim M, et al. Refractory Graves' Disease Successfully Cured by Adjunctive Cholestyramine and Subsequent Total Thyroidectomy. Endocrinol Metab (Seoul) 2015; 30:620.</a></li><li><a class="nounderline abstract_t">Knight CL, Cooray SD, Kulkarni J, et al. Thyroidectomy for the treatment of Graves' thyrotoxicosis in thioamide-induced agranulocytosis and sepsis. Endocrinol Diabetes Metab Case Rep 2017; 2017.</a></li><li><a class="nounderline abstract_t">Erbil Y, Ozluk Y, Giriş M, et al. Effect of lugol solution on thyroid gland blood flow and microvessel density in the patients with Graves' disease. J Clin Endocrinol Metab 2007; 92:2182.</a></li><li><a class="nounderline abstract_t">Randle RW, Bates MF, Long KL, et al. Impact of potassium iodide on thyroidectomy for Graves' disease: Implications for safety and operative difficulty. Surgery 2018; 163:68.</a></li><li><a class="nounderline abstract_t">Tsai CH, Yang PS, Lee JJ, et al. Effects of Preoperative Iodine Administration on Thyroidectomy for Hyperthyroidism: A Systematic Review and Meta-analysis. Otolaryngol Head Neck Surg 2019; 160:993.</a></li><li><a class="nounderline abstract_t">Hughes OR, Scott-Coombes DM. Hypocalcaemia following thyroidectomy for treatment of Graves' disease: implications for patient management and cost-effectiveness. J Laryngol Otol 2011; 125:849.</a></li><li><a class="nounderline abstract_t">Pesce CE, Shiue Z, Tsai HL, et al. Postoperative hypocalcemia after thyroidectomy for Graves' disease. Thyroid 2010; 20:1279.</a></li><li><a class="nounderline abstract_t">Oltmann SC, Brekke AV, Schneider DF, et al. Preventing postoperative hypocalcemia in patients with Graves disease: a prospective study. Ann Surg Oncol 2015; 22:952.</a></li><li><a class="nounderline abstract_t">Kim WW, Chung SH, Ban EJ, et al. Is Preoperative Vitamin D Deficiency a Risk Factor for Postoperative Symptomatic Hypocalcemia in Thyroid Cancer Patients Undergoing Total Thyroidectomy Plus Central Compartment Neck Dissection? Thyroid 2015; 25:911.</a></li><li><a class="nounderline abstract_t">Antakia R, Edafe O, Uttley L, Balasubramanian SP. Effectiveness of preventative and other surgical measures on hypocalcemia following bilateral thyroid surgery: a systematic review and meta-analysis. Thyroid 2015; 25:95.</a></li><li><a class="nounderline abstract_t">Testa A, Fant V, De Rosa A, et al. Calcitriol plus hydrochlorothiazide prevents transient post-thyroidectomy hypocalcemia. Horm Metab Res 2006; 38:821.</a></li><li><a class="nounderline abstract_t">Genser L, Trésallet C, Godiris-Petit G, et al. Randomized controlled trial of alfacalcidol supplementation for the reduction of hypocalcemia after total thyroidectomy. Am J Surg 2014; 207:39.</a></li><li><a class="nounderline abstract_t">Werga-Kjellman P, Zedenius J, Tallstedt L, et al. Surgical treatment of hyperthyroidism: a ten-year experience. Thyroid 2001; 11:187.</a></li><li><a class="nounderline abstract_t">Rubio GA, Koru-Sengul T, Vaghaiwalla TM, et al. Postoperative Outcomes in Graves' Disease Patients: Results from the Nationwide Inpatient Sample Database. Thyroid 2017; 27:825.</a></li><li><a class="nounderline abstract_t">Welch KC, McHenry CR. Total thyroidectomy: is morbidity higher for Graves' disease than nontoxic goiter? J Surg Res 2011; 170:96.</a></li><li><a class="nounderline abstract_t">Bellantone R, Lombardi CP, Raffaelli M, et al. Is routine supplementation therapy (calcium and vitamin D) useful after total thyroidectomy? Surgery 2002; 132:1109.</a></li><li><a class="nounderline abstract_t">Landry CS, Grubbs EG, Hernandez M, et al. Predictable criteria for selective, rather than routine, calcium supplementation following thyroidectomy. Arch Surg 2012; 147:338.</a></li><li><a class="nounderline abstract_t">Noordzij JP, Lee SL, Bernet VJ, et al. Early prediction of hypocalcemia after thyroidectomy using parathyroid hormone: an analysis of pooled individual patient data from nine observational studies. J Am Coll Surg 2007; 205:748.</a></li><li><a class="nounderline abstract_t">Erbil Y, Ozbey NC, Sari S, et al. Determinants of postoperative hypocalcemia in vitamin D-deficient Graves' patients after total thyroidectomy. Am J Surg 2011; 201:685.</a></li><li><a class="nounderline abstract_t">Cote V, Sands N, Hier MP, et al. Cost savings associated with post-thyroidectomy parathyroid hormone levels. Otolaryngol Head Neck Surg 2008; 138:204.</a></li><li><a class="nounderline abstract_t">Edafe O, Antakia R, Laskar N, et al. Systematic review and meta-analysis of predictors of post-thyroidectomy hypocalcaemia. Br J Surg 2014; 101:307.</a></li></ol></div><div id="topicVersionRevision">Topic 7880 Version 23.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27521067" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32079830" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : The American Association of Endocrine Surgeons Guidelines for the Definitive Surgical Management of Thyroid Disease in Adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8768863" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Graves' hyperthyroidism: treatment with antithyroid drugs, surgery, or radioiodine--a prospective, randomized study. Thyroid Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21306240" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Radioiodine therapy for hyperthyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30827829" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Primary therapy of Graves' disease and cardiovascular morbidity and mortality: a linked-record cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30485487" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Thyrotrophin receptor antibody concentration and activity, several years after treatment for Graves' disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33276695" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Ultrasound Assessment of Autonomous Thyroid Nodules before and after Radioiodine Therapy Using Thyroid Imaging Reporting and Data System (TIRADS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3970328" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Substernal goiter. Analysis of 80 patients from Massachusetts General Hospital.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24943236" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Total thyroidectomy is associated with increased risk of complications for low- and high-volume surgeons.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26967630" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Is There a Minimum Number of Thyroidectomies a Surgeon Should Perform to Optimize Patient Outcomes?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10792958" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : The efficacy of thyroidectomy for Graves' disease: A meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29180171" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : The long-term outcomes of thyroid function after subtotal thyroidectomy for Graves' hyperthyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22287122" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Randomized clinical trial of bilateral subtotal thyroidectomy versus total thyroidectomy for Graves' disease with a 5-year follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31634179" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Total Versus Near-total Thyroidectomy in Graves Disease: Results of the Randomized Controlled Multicenter TONIG-trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1814659" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Rapid preoperative preparation in hyperthyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3515594" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : The role of propranolol in the preoperative preparation of patients with Graves' disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6696203" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Preoperative treatment of patients with thyrotoxicosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29966113" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : The safety of anaesthetising biochemically hyperthyroid patients undergoing thyroidectomy-a retrospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37253173" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Surgical Treatment of Hyperthyroidism Can Be Performed Safely Before a Euthyroid State is Achieved.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37253170" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Is the Risk of Thyroid Storm Higher When Patient-Related Factors Delay Treatment of Hyperthyroidism, Or Is It Higher When Patients Undergo Thyroidectomy While Still Thyrotoxic?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3545108" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : The selective beta 1-blocking agent metoprolol compared with antithyroid drug and thyroxine as preoperative treatment of patients with hyperthyroidism. Results from a prospective, randomized study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2242971" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : The role of selective beta 1-blocker in the preoperative preparation of thyrotoxicosis: a comparative study with propranolol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6892650" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Combination of potassium iodide and propranolol in preparation of patients with Graves' disease for thyroid surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26765838" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Rapid preoperative blockage of thyroid hormone production / secretion in patients with Graves' disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26394731" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Refractory Graves' Disease Successfully Cured by Adjunctive Cholestyramine and Subsequent Total Thyroidectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28924483" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Thyroidectomy for the treatment of Graves' thyrotoxicosis in thioamide-induced agranulocytosis and sepsis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17389702" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Effect of lugol solution on thyroid gland blood flow and microvessel density in the patients with Graves' disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29108701" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Impact of potassium iodide on thyroidectomy for Graves' disease: Implications for safety and operative difficulty.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30721111" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Effects of Preoperative Iodine Administration on Thyroidectomy for Hyperthyroidism: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21679493" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Hypocalcaemia following thyroidectomy for treatment of Graves' disease: implications for patient management and cost-effectiveness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20950255" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Postoperative hypocalcemia after thyroidectomy for Graves' disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25212835" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Preventing postoperative hypocalcemia in patients with Graves disease: a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26061175" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Is Preoperative Vitamin D Deficiency a Risk Factor for Postoperative Symptomatic Hypocalcemia in Thyroid Cancer Patients Undergoing Total Thyroidectomy Plus Central Compartment Neck Dissection?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25203484" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Effectiveness of preventative and other surgical measures on hypocalcemia following bilateral thyroid surgery: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17163358" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Calcitriol plus hydrochlorothiazide prevents transient post-thyroidectomy hypocalcemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24119718" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Randomized controlled trial of alfacalcidol supplementation for the reduction of hypocalcemia after total thyroidectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11288990" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Surgical treatment of hyperthyroidism: a ten-year experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28457178" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Postoperative Outcomes in Graves' Disease Patients: Results from the Nationwide Inpatient Sample Database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21550063" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Total thyroidectomy: is morbidity higher for Graves' disease than nontoxic goiter?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12490862" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Is routine supplementation therapy (calcium and vitamin D) useful after total thyroidectomy?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22184134" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Predictable criteria for selective, rather than routine, calcium supplementation following thyroidectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18035257" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Early prediction of hypocalcemia after thyroidectomy using parathyroid hormone: an analysis of pooled individual patient data from nine observational studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21545922" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Determinants of postoperative hypocalcemia in vitamin D-deficient Graves' patients after total thyroidectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18241717" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Cost savings associated with post-thyroidectomy parathyroid hormone levels.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24402815" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Systematic review and meta-analysis of predictors of post-thyroidectomy hypocalcaemia.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
